Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden

This database study compares surveillance data on immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors to determine whether irAEs experienced during anti–PD-1 therapy correlate with tumor mutational burden across 18 cancer types.

Detalles Bibliográficos
Autores principales: Bomze, David, Hasan Ali, Omar, Bate, Andrew, Flatz, Lukas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707013/
https://www.ncbi.nlm.nih.gov/pubmed/31436791
http://dx.doi.org/10.1001/jamaoncol.2019.3221
_version_ 1783445797255249920
author Bomze, David
Hasan Ali, Omar
Bate, Andrew
Flatz, Lukas
author_facet Bomze, David
Hasan Ali, Omar
Bate, Andrew
Flatz, Lukas
author_sort Bomze, David
collection PubMed
description This database study compares surveillance data on immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors to determine whether irAEs experienced during anti–PD-1 therapy correlate with tumor mutational burden across 18 cancer types.
format Online
Article
Text
id pubmed-6707013
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-67070132019-09-06 Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden Bomze, David Hasan Ali, Omar Bate, Andrew Flatz, Lukas JAMA Oncol Research Letter This database study compares surveillance data on immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors to determine whether irAEs experienced during anti–PD-1 therapy correlate with tumor mutational burden across 18 cancer types. American Medical Association 2019-08-22 2019-11 /pmc/articles/PMC6707013/ /pubmed/31436791 http://dx.doi.org/10.1001/jamaoncol.2019.3221 Text en Copyright 2019 Bomze D et al. JAMA Oncology. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Research Letter
Bomze, David
Hasan Ali, Omar
Bate, Andrew
Flatz, Lukas
Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden
title Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden
title_full Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden
title_fullStr Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden
title_full_unstemmed Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden
title_short Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden
title_sort association between immune-related adverse events during anti–pd-1 therapy and tumor mutational burden
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707013/
https://www.ncbi.nlm.nih.gov/pubmed/31436791
http://dx.doi.org/10.1001/jamaoncol.2019.3221
work_keys_str_mv AT bomzedavid associationbetweenimmunerelatedadverseeventsduringantipd1therapyandtumormutationalburden
AT hasanaliomar associationbetweenimmunerelatedadverseeventsduringantipd1therapyandtumormutationalburden
AT bateandrew associationbetweenimmunerelatedadverseeventsduringantipd1therapyandtumormutationalburden
AT flatzlukas associationbetweenimmunerelatedadverseeventsduringantipd1therapyandtumormutationalburden

Ejemplares similares